Revvity

Company Snapshot

Founded: 1937
Entity Type: Public
Employees: 11,000
Region: U.S.
Revenue: $2,755.0 Millions
Revenue Year: 2024
Headquarter: Waltham, Massachusetts, U.S.
Key Geographics: U.K., U.S., China, Rest of the World

Company Overview

The PerkinElmer Life Sciences and Diagnostics Company, renamed during the second quarter of 2023 is a leading provider of health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development and diagnosis to cure. Revvity offers comprehensive solutions in reagents, consumables, assays, instruments, and software to various markets, including pharma, biotech, diagnostic labs, academia, and government agencies.

The company manages its business in two segments: Life Sciences and Diagnostics. Life Sciences provides products and services targeted towards life sciences customers. The Diagnostics segment is especially focused on reproductive health, immunodiagnostics, emerging market diagnostics and applied genomics. Revvity Omics offers genomic testing focused on rare inherited diseases, newborn screening, and hereditary cancers. The offered services support the full continuum of care from preconception and prenatal to neonatal, pediatrics, and adult.

Revvity Omics is a global laboratory network offering multi-OMIC clinical grade services for testing in cytogenetics, biochemical genetics (prenatal and postnatal), molecular genetics and immunodiagnostics. The laboratory network includes testing laboratories in the U.S., Sweden, India, China and the U.K.

Revvity In Reports

Separation Systems for Commercial Biotechnology

According to BCC Research detailed report on Separation Systems for Commercial Biotechnology market report includes global revenue ($ million) for base year data 2024, estimated data for 2025, and forecast data for 2026...

Global Viral Vector Manufacturing Markets and Technologies Through 2030

According to BCC Research detailed report on the viral vector manufacturing market data will be provided for 2024 because of the base year, with forecasts for 2025 and forecast value for 2030.

Biological and Medical Imaging Reagents: Global Markets

BCC Research Report: Dive into biological and medical imaging reagents market revenues are broken down by region and have been estimated for the five-year period from 2024 through 2029.

Company's Business Segments

  • Life Sciences : Sales of instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services
  • Diagnostics : Sales of instruments, solutions, consumables, reagents, and services

Applications/End User Industries

  • Hospitals
  • Medical Labs
  • Clinicians
  • Medical Research Professionals
  • Research Institutions
  • Pharmaceutical
AI: Your Say